Clinical trial · Interventional
Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)
NCT06455124CI-TRIAL-00077947recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single arm phase II study to explore the 3y LRFS and safety for high-risk early rectal cancer after local excision with short-course radiotherapy and chemo-immunotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rectal Cancer | Malignant Rectal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Capecitabine | Drug | Capecitabine | ALIAS |
| Oxaliplatin | Drug | Oxaliplatin | ALIAS |
| PD-1 antibody | Drug | — | UNRESOLVED |
| Radiation | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Arm1
- description
- Patients will receive short course radiotherapy and four cycles of CapeOx and PD-1 inhibitor.
- interventionNames
- Radiation: Radiation
- Drug: PD-1 antibody
- Drug: Capecitabine
- Drug: Oxaliplatin
Primary outcomes (1)
- measure
- 3y LRFS
- timeFrame
- From date of initiation of treatment until the date of first documented pelvic failure, assessed up to 36 months.
- description
- Rate of 3 year local recurrence free survival rate
Secondary outcomes (3)
- measure
- 3y DFS
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. age 18-75 years old, female and male 2. pathological confirmed adenocarcinoma 3. the distance from anal verge ≤ 7 cm 4. pT1 after local excision of the primary rectal cancer, with at least one of the high-risk features including margin positivity/very close margin (\<1mm) at time of local excision, depth of invasion \>1 mm or SM3 invasion (submucosal invasion to the lower third of the submucosal level), high grade or poorly differentiated, lymphovascular invasion, perineural invasion, tumour budding, or pT2 tumor. 5. refuse radical surgery 6. without pelvic or distance metastases 7. KPS \>=70 8. with good compliance 9. microsatellite repair status is MSS/pMMR 10. without previous anti-cancer therapy or immunotherapy 11. signed the inform consent Exclusion Criteria: 1. pregnancy or breast-feeding women 2. pathological confirmed signet ring cell carcinoma 3. history of other malignancies within 5 years 4. serious medical illness, such as severe mental disorders, cardiac disease, uncontrolled infection, etc. 5. immunodeficiency disease or long-term using of immunosuppressive agents 6. baseline blood and biochemical indicators do not meet the following criteria: neutrophils≥1.5×10\^9/L, Hb≥90g/L, PLT≥100×10\^9/L, ALT/AST ≤2.5 ULN, Cr≤ 1 ULN 7. DPD deficiency 8. allergic to any component of the therapy
References
Publications (0)
Data not yet available
No reference posted for this study.